Gilmore, Robert B

Hilley, Patrick

Srinivasan, Ashish

Choy, Matthew C

De Cruz, Peter P

2022

Preliminary data regarding the effectiveness of tofacitinib in acute severe ulcerative colitis (ASUC) have been presented in two previous case series. We aimed to describe the novel use of high-dose tofacitinib immediately following non-response to infliximab in the setting of steroid-refractory acute severe ulcerative colitis (ASUC). Five patients who received high-dose tofacitinib 10mg three times a day immediately following non-response to infliximab for steroid-refractory ASUC were identified at an Australian tertiary inflammatory bowel disease centre. Four of 5 patients demonstrated clinical response to high-dose tofacitinib induction during their inpatient admission, with one patient requiring colectomy owing to a lack of clinical response. At 90 days, all four initial responders remained colectomy-free, with two patients achieving combined clinical and endoscopic remission. No adverse events directly attributable to high-dose tofacitinib were identified. High-dose tofacitinib may have a role as salvage therapy in the setting of steroid-refractory ASUC. Prospective studies are required to determine the safety and efficacy of high-dose tofacitinib to determine whether it can be routinely recommended as primary or sequential salvage therapy in the setting of steroid-refractory ASUC.

Journal of Crohn's & Colitis 2022; 16(1): 166-168

Journal of Crohn's & Colitis

0000-0001-5952-1570

https://ahro.austin.org.au/austinjspui/handle/1/26809

Acute Severe Ulcerative Colitis

Infliximab

Tofacitinib

Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.

Journal Article